<DOC>
	<DOCNO>NCT00613418</DOCNO>
	<brief_summary>This prospective , multicenter , non-randomized , single-arm trial ; primary objective ass comparability performance IDev SUPERA® nitinol stent rate derive meta-analysis study iliac stent approve FDA treat subject de novo restenotic lesion common and/or external iliac artery .</brief_summary>
	<brief_title>Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery</brief_title>
	<detailed_description />
	<criteria>1 . Subject 18 year age old legal age consent . 2 . Subject lifestyle limit claudication rest pain ( RutherfordBecker scale 2 , 3 4 ) . 3 . Subject de novo restenotic lesion common external iliac artery . 4 . Subject single , bilateral multiple target lesion ( ) ≥ 50 % stenosed visual estimate . 5 . The target lesion ( ) successfully cross guide wire dilate . 6 . The target segment subject 's lesion ( ) 4 10 mm diameter le 110 mm length . 7 . Subject angiographic evidence patent femoral outflow artery target limb . 8 . Subject provide write informed consent . 9 . Subject able willing adhere require followup visit test month 36 . 10 . Subject able willing adhere require followup medication regimen 1 . Presence nontarget arterial lesion require treatment within 30 day procedure . 2 . The target lesion ( ) adjacent , acute thrombus . 3 . The target lesion ( ) highly calcify previously treat stent . 4 . Subject preexist target iliac artery perforation dissection target iliac artery prior initiation IDev implant procedure . 5 . Subject abdominal aortic aneurysm contiguous iliac artery target lesion . Subject preexist aneurysm dissection target iliac segment . 6 . Subject aortic iliac aneurysm likely require repair within next 9 month . 7 . Subject postsurgical stenosis anastomotic suture treatment target vessel . 8 . Subject vascular graft previously implant native iliac vessel . 9 . Subject tissue loss , define RutherfordBecker classification category 5 6 . 10 . Subject unable accommodate ≥ 7 Fr cat 11 . Subject contrast agent hypersensitivity adequately premedicated , hypersensitivity nickel , intolerance antiplatelet , anticoagulant , thrombolytic medication . 12 . Subject history neutropenia ( WBC &lt; 3,000/mm3 ) . 13 . Subject coagulopathy thrombocytopenia ( platelet count &lt; 80,000/ μL ) resolve require treatment past 6 month . 14 . Subject know bleeding hypercoagulability disorder significant anemia ( Hb &lt; 8.0 g/dL ) correct . 15 . Subject follow laboratory value : 1. international normalize ratio ( INR ) great 1.5 , 2. serum creatinine level great 2.5 mg/dL . 16 . Subject require general anesthesia procedure . 17 . Subject pregnant plan become pregnant study . 18 . Subject comorbid illness may result life expectancy le 1 year . 19 . Subject participate investigational study new drug , biologic device time study screen . NOTE : Subjects participate long term followup phase previously investigational FDAapproved product exclude criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>